DE602006010064D1 - Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer - Google Patents

Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer

Info

Publication number
DE602006010064D1
DE602006010064D1 DE602006010064T DE602006010064T DE602006010064D1 DE 602006010064 D1 DE602006010064 D1 DE 602006010064D1 DE 602006010064 T DE602006010064 T DE 602006010064T DE 602006010064 T DE602006010064 T DE 602006010064T DE 602006010064 D1 DE602006010064 D1 DE 602006010064D1
Authority
DE
Germany
Prior art keywords
vaccines
intranasal
administrative
treatment
highly safe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010064T
Other languages
English (en)
Inventor
Hideo Hara
Takeshi Tabira
Yoshikazu Yonemitsu
Makoto Inoue
Yumiko Tokusumi
Mamoru Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN GOVERNMENT
Dnavec Corp
Original Assignee
JAPAN GOVERNMENT
Dnavec Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JAPAN GOVERNMENT, Dnavec Corp filed Critical JAPAN GOVERNMENT
Publication of DE602006010064D1 publication Critical patent/DE602006010064D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602006010064T 2005-04-20 2006-04-20 Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer Active DE602006010064D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005123015 2005-04-20
US72769005P 2005-10-18 2005-10-18
PCT/JP2006/308913 WO2006112553A2 (en) 2005-04-20 2006-04-20 Highly safe intranasally administrable gene vaccines for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
DE602006010064D1 true DE602006010064D1 (de) 2009-12-10

Family

ID=37056591

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006010064T Active DE602006010064D1 (de) 2005-04-20 2006-04-20 Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer

Country Status (7)

Country Link
US (1) US20090170798A1 (de)
EP (1) EP1891215B1 (de)
KR (1) KR20080031167A (de)
AU (1) AU2006237903A1 (de)
CA (1) CA2605957A1 (de)
DE (1) DE602006010064D1 (de)
WO (1) WO2006112553A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001244675A1 (en) 2000-03-30 2001-10-08 Dnavec Research Inc. Aids virus vaccine with the use of sendai virus vector
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
JPWO2005042737A1 (ja) * 2003-11-04 2007-05-10 株式会社ディナベック研究所 遺伝子導入された樹状細胞の製造方法
US8741650B2 (en) * 2004-01-22 2014-06-03 Dnavec Research Inc. Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken β-actin promoter
EP1775343A4 (de) * 2004-06-24 2007-11-14 Dnavec Research Inc Antitumormittel mit dendritischer zelle mit darin transfiziertem rna-virus
EP1916298B1 (de) * 2005-06-14 2011-12-28 Dnavec Corporation Verfahren zur herstellung von monoklonalen antikörpern
US20100167341A1 (en) * 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
JPWO2010050585A1 (ja) * 2008-10-31 2012-03-29 ディナベック株式会社 アルツハイマー病治療用ベクター
JP5697044B2 (ja) 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
AU2001244675A1 (en) * 2000-03-30 2001-10-08 Dnavec Research Inc. Aids virus vaccine with the use of sendai virus vector
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
JP4888876B2 (ja) * 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター

Also Published As

Publication number Publication date
CA2605957A1 (en) 2006-10-26
US20090170798A1 (en) 2009-07-02
WO2006112553A2 (en) 2006-10-26
KR20080031167A (ko) 2008-04-08
WO2006112553A3 (en) 2007-02-22
EP1891215A2 (de) 2008-02-27
AU2006237903A1 (en) 2006-10-26
EP1891215B1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
DE602006010064D1 (de) Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE549330T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
IL190913A0 (en) Methods for the treatment of hyperhidrosis
DE602005013775D1 (de) Verbesserte methode zur transformation von sojabohnen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602006009764D1 (de) Terphenylderivate zur Alzheimerbehandlung
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
DE602006010302D1 (de) Verfahren zur Herstellung von 5-methyl-2-furfural
DE602006009562D1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE537178T1 (de) Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten
ATE516805T1 (de) Medikament zur behandlung von endometriose
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602006008022D1 (de) Verfahren zur herstellung von duloxetin
DE602006003456D1 (de) Verfahren zur Herstellung von Polyoxyalkylen-Organopolysiloxan-Copolymeren
DE502006008973D1 (de) Verfahren zur Herstellung von Methylchlorsilanen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition